EA201492109A1 - Композиции активатора глюкокиназы для лечения сахарного диабета - Google Patents

Композиции активатора глюкокиназы для лечения сахарного диабета

Info

Publication number
EA201492109A1
EA201492109A1 EA201492109A EA201492109A EA201492109A1 EA 201492109 A1 EA201492109 A1 EA 201492109A1 EA 201492109 A EA201492109 A EA 201492109A EA 201492109 A EA201492109 A EA 201492109A EA 201492109 A1 EA201492109 A1 EA 201492109A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
diabetes mellitus
treating diabetes
glucokinase activator
diabetes
Prior art date
Application number
EA201492109A
Other languages
English (en)
Inventor
Мария Кармен Валкарсе Лопес
Тунг Фонг
Original Assignee
ТРАНСТЕК ФАРМА ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТРАНСТЕК ФАРМА ЭлЭлСи filed Critical ТРАНСТЕК ФАРМА ЭлЭлСи
Publication of EA201492109A1 publication Critical patent/EA201492109A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим композициям, включающим {2-[3-циклогексил-3-(транс-4-пропоксициклогексил)уреидо]тиазол-5-ил-сульфанил}уксусную кислоту (FRI-1) в комбинации с антидиабетическим лекарственным средством, выбираемым из группы, состоящей из метформина, ситаглиптина или эксенатида. Настоящее изобретение также относится к применению фармацевтических композиций для восстановления чувствительности к инсулину и лечения сахарного диабета II типа, включающего снижение массы тела субъекта, который получает лечение от сахарного диабета II типа.
EA201492109A 2012-05-17 2013-05-15 Композиции активатора глюкокиназы для лечения сахарного диабета EA201492109A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648110P 2012-05-17 2012-05-17
PCT/US2013/041076 WO2013173417A2 (en) 2012-05-17 2013-05-15 Glucokinase activator compositions for the treatment of diabetes

Publications (1)

Publication Number Publication Date
EA201492109A1 true EA201492109A1 (ru) 2015-07-30

Family

ID=48576527

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492109A EA201492109A1 (ru) 2012-05-17 2013-05-15 Композиции активатора глюкокиназы для лечения сахарного диабета

Country Status (16)

Country Link
US (3) US10004782B2 (ru)
EP (1) EP2849776B1 (ru)
JP (1) JP6234443B2 (ru)
KR (2) KR102371364B1 (ru)
CN (2) CN104349790A (ru)
AU (2) AU2013262895A1 (ru)
BR (1) BR112014028622A2 (ru)
CA (1) CA2872021C (ru)
EA (1) EA201492109A1 (ru)
ES (1) ES2878001T3 (ru)
HK (1) HK1202458A1 (ru)
IL (1) IL235484A0 (ru)
IN (1) IN2014DN09554A (ru)
MX (1) MX360304B (ru)
SG (2) SG10201609644UA (ru)
WO (1) WO2013173417A2 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101860120B1 (ko) 2010-05-26 2018-05-23 브이티브이 테라퓨틱스 엘엘씨 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
ES2878001T3 (es) * 2012-05-17 2021-11-18 Vtv Therapeutics Llc Composiciones del activador de la glucocinasa para el tratamiento de la diabetes
KR102408480B1 (ko) 2018-05-30 2022-06-10 이삼구 당뇨질환의 치료용 조성물
KR102703153B1 (ko) * 2018-05-31 2024-09-06 후아 메디슨 (상하이) 엘티디. 글루코키나제 활성화제 및 k-atp 채널 차단제를 함유하는 약제학적 병용물, 조성물 및 병용 제제, 및 이의 제조 방법 및 이의 용도
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US11872221B2 (en) 2020-01-31 2024-01-16 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator
AU2020426356A1 (en) * 2020-01-31 2022-08-25 Hua Medicine (Shanghai) Ltd. Treating treatment-resistant diabetes with glucokinase activator
US11857536B2 (en) 2020-06-04 2024-01-02 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
AU2020451588A1 (en) * 2020-06-04 2023-01-19 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
US20230219909A1 (en) * 2020-06-08 2023-07-13 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
WO2021252309A1 (en) * 2020-06-08 2021-12-16 Vtv Therapeutics Llc Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof
CN115350268A (zh) * 2022-08-24 2022-11-18 深圳青澜生物技术有限公司 一种用于治疗糖尿病的制剂、微针及其制备工艺

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT323195B (de) 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
FR2243684B1 (ru) 1973-09-19 1977-01-28 Semb
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
US6660716B1 (en) * 1999-06-21 2003-12-09 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6608038B2 (en) * 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
AU2004215514B2 (en) 2003-02-26 2010-03-04 Msd K.K. Heteroarylcarbamoylbenzene derivative
KR20060052650A (ko) * 2003-07-14 2006-05-19 소니 가부시끼 가이샤 정보제공방법
WO2005023766A1 (en) 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
ES2399052T3 (es) * 2004-01-06 2013-03-25 Novo Nordisk A/S Heteroaril-ureas y su uso como activadores de glucocinasa
CN1910166B (zh) * 2004-01-06 2012-01-04 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
EP1758611A2 (en) * 2004-06-17 2007-03-07 Novo Nordisk A/S Use of liver-selective glucokinase activators
WO2006110809A2 (en) 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US20100028439A1 (en) 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
CN101258137A (zh) * 2005-07-08 2008-09-03 诺沃-诺迪斯克有限公司 双环烷基脲葡糖激酶活化剂
JP2009500378A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
JP2009500377A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
AU2006268589B2 (en) 2005-07-14 2011-09-29 Vtv Therapeutics Llc Urea glucokinase activators
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
EP2118083A1 (en) 2007-01-09 2009-11-18 Novo Nordisk A/S Urea glucokinase activators
KR20110018366A (ko) 2008-05-16 2011-02-23 다케다 샌디에고, 인코포레이티드 글루코키나아제 활성제
US8680230B2 (en) 2008-07-22 2014-03-25 Kureha Corporation Production process of poly(arylene sulfide) whose content of terminal halogen group has been reduced
WO2010107610A1 (en) * 2009-03-17 2010-09-23 Merck Sharp & Dohme Corp. Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds
SG2014012553A (en) 2009-04-16 2014-05-29 Taisho Pharmaceutical Co Ltd Pharmaceutical compositions
KR101190957B1 (ko) 2009-08-25 2012-10-15 한올바이오파마주식회사 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101860120B1 (ko) * 2010-05-26 2018-05-23 브이티브이 테라퓨틱스 엘엘씨 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
EP2392575A1 (en) * 2010-06-04 2011-12-07 LEK Pharmaceuticals d.d. A novel synthetic approach to ß-aminobutyryl substituted compounds
ES2878001T3 (es) 2012-05-17 2021-11-18 Vtv Therapeutics Llc Composiciones del activador de la glucocinasa para el tratamiento de la diabetes
JP6441828B2 (ja) 2013-03-04 2018-12-19 ブイティーブイ・セラピューティクス・エルエルシー 安定なグルコキナーゼ活性化剤組成物
KR102694699B1 (ko) 2013-03-04 2024-08-12 브이티브이 테라퓨틱스 엘엘씨 글루코키나제 활성화제를 포함하는 고체 조성물 및 그것의 제조 및 사용 방법

Also Published As

Publication number Publication date
KR20150013838A (ko) 2015-02-05
US10980861B2 (en) 2021-04-20
US10004782B2 (en) 2018-06-26
KR20210027547A (ko) 2021-03-10
JP6234443B2 (ja) 2017-11-22
EP2849776A2 (en) 2015-03-25
US20200138909A1 (en) 2020-05-07
AU2017203835B2 (en) 2018-11-22
IN2014DN09554A (ru) 2015-07-17
CA2872021A1 (en) 2013-11-21
SG10201609644UA (en) 2017-01-27
US20180311314A1 (en) 2018-11-01
MX2014013105A (es) 2015-04-08
WO2013173417A2 (en) 2013-11-21
CA2872021C (en) 2022-08-16
AU2017203835A1 (en) 2017-06-22
US20140066372A1 (en) 2014-03-06
US10588943B2 (en) 2020-03-17
HK1202458A1 (en) 2015-10-02
IL235484A0 (en) 2014-12-31
AU2013262895A1 (en) 2014-11-13
WO2013173417A3 (en) 2014-02-20
CN104349790A (zh) 2015-02-11
BR112014028622A2 (pt) 2017-06-27
MX360304B (es) 2018-10-29
CN118453592A (zh) 2024-08-09
ES2878001T3 (es) 2021-11-18
JP2015517525A (ja) 2015-06-22
KR102371364B1 (ko) 2022-03-07
EP2849776B1 (en) 2021-04-21
SG11201406987UA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
EA201492109A1 (ru) Композиции активатора глюкокиназы для лечения сахарного диабета
RS52629B (en) LIXISENATIDE AS ADDITIONAL THERAPY INSULIN GLARGINE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT
CL2009001340A1 (es) Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto.
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
BR112015014510A2 (pt) agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
JP2011241213A5 (ru)
BR112014023374A2 (pt) composições de peptídeos de glp-1 e preparação das mesmas
EA201190048A1 (ru) Аналоги глюкагона
EA201892383A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
EA202090593A2 (ru) Пептидное соединение
EA201991014A1 (ru) Лечение диабета
EA201590715A1 (ru) Производные эксендина-4 как двойные агонисты glp1/глюкагона
EA201590058A1 (ru) Аналоги глюкагона
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
EA201190054A1 (ru) Аналоги глюкагона
EA201190047A1 (ru) Аналоги глюкагона
EA201190049A1 (ru) Аналоги глюкагона
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
EA201490982A1 (ru) Аналоги глюкагона
EA201491335A1 (ru) Бигуанидные композиции и способы лечения метаболических расстройств
CL2014001437A1 (es) Compuestos derivados de aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2); composicion y combinacion farmaceutica; y uso en el tratamiento y prevencion de diabetes, hiperglucemia, retinopatia, sindrome metabolico, entre otras enfermedades.
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
PH12015501931B1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
EA201792030A1 (ru) Лечение пациентов с сахарным диабетом 2 типа